Julian Adams is a businessperson who has been at the helm of 5 different companies. Currently, he occupies the position of Chairman of Elicio Therapeutics, Inc. and Chief Executive Officer & Director at Gamida Cell Ltd., Chief Executive Officer & Director at Gamida Cell, Inc. (a subsidiary of Gamida Cell Ltd.). Dr. Adams is also on the board of Princess Margaret Cancer Foundation.
Julian Adams previously occupied the position of President & Chief Science Officer at Clal Biotechnology Industries Ltd. and President & Chief Science Officer at Clal Biotechnology Industries Ltd. (Venture Capital) (a subsidiary of Clal Biotechnology Industries Ltd.), President-Research & Development at Infinity Pharmaceuticals, Inc. and President for Infinity Discovery, Inc. (a subsidiary of Infinity Pharmaceuticals, Inc.), Medicinal Chemist at Merck & Co., Inc., Advisor at Limulus Management Co. LLC, Senior Vice President-Research & Development at LeukoSite, Inc., Director, Executive VP-Research & Development at ProScript, Inc., Senior Vice President-Drug Discovery & Development at Millennium Pharmaceuticals, Inc. and Director-Medicinal Chemistry at Boehringer Ingelheim Corp.
Dr. Adams received an undergraduate degree from McGill University and a doctorate from Massachusetts Institute of Technology.
|07/27/2022||68,800||Award at $0 per share.||0|
|07/27/2022||48,500||Award at $0 per share.||0|